Unknown

Dataset Information

0

Association of Very Early Serum Levels of S100B, Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and Spectrin Breakdown Product with Outcome in ProTECT III.


ABSTRACT: Rapid risk-stratification of patients with acute traumatic brain injury (TBI) would inform management decisions and prognostication. The objective of this serum biomarker study (Biomarkers of Injury and Outcome [BIO]-Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment [ProTECT]) was to test the hypothesis that serum biomarkers of structural brain injury, measured at a single, very early time-point, add value beyond relevant clinical covariates when predicting unfavorable outcome 6 months after moderate-to-severe acute TBI. BIO-ProTECT utilized prospectively collected samples obtained from subjects with moderate-to-severe TBI enrolled in the ProTECT III clinical trial of progesterone. Serum samples were obtained within 4?h after injury. Glial fibrillary acidic protein (GFAP), S100B, ?II-spectrin breakdown product of molecular weight 150 (SBDP150), and ubiquitin C-terminal hydrolase-L1 (UCH-L1) were measured. The association between log-transformed biomarker levels and poor outcome, defined by a Glasgow Outcome Scale-Extended (GOS-E) score of 1-4 at 6 months post-injury, were estimated via logistic regression. Prognostic models and a biomarker risk score were developed using bootstrapping techniques. Of 882 ProTECT III subjects, samples were available for 566. Each biomarker was associated with 6-month GOS-E (p?

SUBMITTER: Frankel M 

PROVIDER: S-EPMC6761588 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Association of Very Early Serum Levels of S100B, Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and Spectrin Breakdown Product with Outcome in ProTECT III.

Frankel Michael M   Fan Liqiong L   Yeatts Sharon D SD   Jeromin Andreas A   Vos Pieter E PE   Wagner Amy K AK   Wolf Bethany J BJ   Pauls Qi Q   Lunney Michael M   Merck Lisa H LH   Hall Casey L CL   Palesch Yuko Y YY   Silbergleit Robert R   Wright David W DW  

Journal of neurotrauma 20190709 20


Rapid risk-stratification of patients with acute traumatic brain injury (TBI) would inform management decisions and prognostication. The objective of this serum biomarker study (Biomarkers of Injury and Outcome [BIO]-Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment [ProTECT]) was to test the hypothesis that serum biomarkers of structural brain injury, measured at a single, very early time-point, add value beyond relevant clinical covariates when predicting unfavorable out  ...[more]

Similar Datasets

| S-EPMC6913786 | biostudies-literature
| S-EPMC6039567 | biostudies-literature
| S-EPMC3965455 | biostudies-literature
| S-EPMC8820878 | biostudies-literature
| S-EPMC4574122 | biostudies-other
| S-EPMC9409281 | biostudies-literature
| S-EPMC11259701 | biostudies-literature
| S-EPMC4722555 | biostudies-literature
| S-EPMC8252046 | biostudies-literature
| S-EPMC3880090 | biostudies-literature